Lido Advisors’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Lido Advisors’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-5,800	Closed	-$597K	–	1344
2023 Q2	$597K	Buy	+5,800	New	+$612K	﹤0.01%	680
2022 Q4	–	Sell	-5,800	Closed	-$358K	–	1096
2022 Q3	$358K	Hold	5,800	–	–	﹤0.01%	670
2022 Q2	$462K	Hold	5,800	–	–	0.01%	571
2022 Q1	$610K	Hold	5,800	–	–	0.01%	541
2021 Q4	$625K	Hold	5,800	–	–	0.01%	543
2021 Q3	$635K	Buy	+5,800	New	+$602K	0.01%	511

Other funds holding HZNP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Lido Advisors's HZNP Position: Q3 2023 in Review

Lido Advisors sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q3 2023, closing a stake of 4,979 shares — an estimated $512K sold.

Lido Advisors first reported a position in HZNP in Q3 2021 and held it in 8 quarters. The position peaked at $1.1M in Q4 2021. 485 funds tracked by Wall St. Rank hold HZNP as of Q3 2023.

Lido Advisors reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q3 2023 after selling out during the quarter.
Lido Advisors sold 4,979 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q3 2023, an estimated $512K.
Lido Advisors first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q3 2021 and held it in 8 quarters.
Lido Advisors's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $1.1M in Q4 2021.
485 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q3 2023.

Based on Lido Advisors's 13F filing for Q3 2023, filed 14 Nov 2023.